Weight Regain After Stopping Mounjaro: What the SURMOUNT-4 Data Shows

Weight regain after stopping Mounjaro is one of the most common concerns I hear from patients in clinic. It is also one of the most important, because the data now available paints a clear picture: for the majority of people, discontinuing tirzepatide leads to significant weight regain within 12 months, alongside a reversal of the metabolic improvements gained during treatment.

Understanding why this happens and what you can do about it requires a close look at the clinical evidence. The SURMOUNT-4 post-hoc analysis, published in JAMA Internal Medicine in November 2025, provides the most detailed picture yet of what happens when tirzepatide is withdrawn. Below, I will walk you through the key findings and what they mean for anyone considering, currently using, or planning to stop Mounjaro.

Yes, most people do regain weight after stopping Mounjaro. The SURMOUNT-4 post-hoc analysis found that 82.5% of participants who discontinued tirzepatide regained at least 25% of the weight they had lost within one year. The average weight regain was 14 percentage points. Importantly, cardiometabolic improvements in areas such as blood pressure, blood sugar control, and cholesterol also reversed in proportion to the degree of weight regain. This does not mean Mounjaro is ineffective. Rather, it confirms that obesity is a chronic condition requiring ongoing management, whether through continued medication, structured lifestyle changes, or a carefully planned transition off treatment.

The SURMOUNT-4 trial was a phase 3 randomised withdrawal study conducted across 70 sites in four countries. Participants first completed a 36-week open-label lead-in period during which they received tirzepatide at the maximum tolerated dose. By the end of this phase, participants had lost an average of 20.9% of their body weight, with 92.7% reaching the maximum dose of 15 mg weekly.

Subsequently, participants were randomised 1:1 to either continue tirzepatide or switch to placebo for a further 52 weeks. This design allowed researchers to observe exactly what happens when Mounjaro is stopped after a sustained period of effective weight loss.

The post-hoc analysis, led by Horn and colleagues, focused specifically on 308 participants in the placebo arm who had achieved at least 10% weight loss during the lead-in period. Their average weight loss at randomisation was 21.9%, providing a robust baseline from which to measure regain.

The headline finding is striking. Of the 308 participants who stopped tirzepatide, 254 (82.5%) regained at least 25% of the weight they had originally lost within 12 months. The breakdown by severity of regain is equally informative:

• 17.5% (54 participants) regained less than 25% of lost weight
• 25.0% (77 participants) regained between 25% and 50%
• 33.4% (103 participants) regained between 50% and 75%
• 24.0% (74 participants) regained 75% or more of their lost weight

In practical terms, the placebo group regained an average of 14.0 percentage points of body weight over the year, while the group that continued tirzepatide lost a further 5.5 percentage points. The difference between the two arms was 19.4 percentage points (P<.001). By the end of the 88-week study period, those who continued Mounjaro had achieved a net weight loss of 25.3%, compared with just 9.9% for those who stopped.

Furthermore, the data revealed that weight regain was not a gradual, linear process. Significant regain typically began around eight weeks after discontinuation, accelerating over the following months. A separate Cambridge meta-analysis estimated a regain rate of approximately 0.8 kg per month for those stopping GLP-1 receptor agonists, with a projected return to baseline weight within 1.5 to 1.7 years.

Perhaps the most clinically significant aspect of the SURMOUNT-4 post-hoc analysis is the demonstration that cardiometabolic improvements reversed in direct proportion to the degree of weight regain. This is not simply about aesthetics or clothing size. It is about cardiovascular risk, diabetes progression, and long-term health outcomes.

The researchers stratified participants into four groups based on their degree of weight regain and measured changes in key metabolic markers. The results were compelling:

• Waist circumference increased by 0.8 cm in those with minimal regain (<25%), but by 14.7 cm in those who regained 75% or more (P<.001)
• Systolic blood pressure rose across all groups, from +6.8 mmHg in the lowest regain group to +10.4 mmHg in the highest (P=.002)
• HbA1c worsened by 0.14 percentage points with minimal regain and by 0.35 percentage points with the most severe regain (P<.001)
• Non-HDL cholesterol fell slightly (-0.4%) in the lowest regain group but rose by 10.8% in those with the greatest regain
• Fasting insulin actually improved (-4.0%) in those with minimal regain, but surged by 46.2% in the 50-75% regain group

Notably, those who kept their regain below 25% largely preserved their improvements in waist circumference, non-HDL cholesterol, and fasting insulin. However, blood pressure and HbA1c worsened even in this group, suggesting that tirzepatide exerts direct pharmacological effects on these parameters that reverse upon withdrawal, regardless of weight trajectory.

As the Pharmaceutical Journal reported in November 2025, these findings reinforce the view that the health benefits of Mounjaro extend beyond weight loss itself, and that stopping the medication risks losing both the weight-dependent and weight-independent metabolic advantages.

To understand weight regain after stopping Mounjaro, it helps to appreciate what the medication does at a physiological level. Tirzepatide is a dual GIP and GLP-1 receptor agonist. It reduces appetite by acting on brain centres that regulate hunger and satiety, slows gastric emptying, and improves insulin sensitivity. When the drug is withdrawn, these effects disappear.

Consequently, appetite returns to pre-treatment levels, often quite abruptly. Patients frequently describe a sudden return of food cravings and a loss of the sense of fullness after smaller meals. The body’s energy homeostasis mechanisms revert to their baseline set point.

Additionally, the metabolic adaptations that accompany significant weight loss work against maintenance. Resting metabolic rate decreases, leptin falls, and the hunger hormone ghrelin rises. These compensatory mechanisms evolved to protect against starvation, but in the context of intentional weight loss they drive regain. The 2025 ACC Expert Consensus Statement explicitly acknowledges this, stating that obesity medications should not be discontinued because weight regain is commonly expected.

It is also worth noting the scale of real-world discontinuation. Danish registry data from a cohort of over 77,000 semaglutide users found that 52% stopped the medication within one year. Of those who discontinued, 42% restarted within the following year, suggesting that many patients experience the consequences of stopping and choose to resume treatment.

While the SURMOUNT-4 data may seem discouraging, the clinical picture is more nuanced than the headlines suggest. The 17.5% of participants who maintained at least 75% of their weight loss demonstrate that sustained success after stopping Mounjaro is possible, even if it is not the norm.

Based on the evidence and my clinical experience, several strategies can meaningfully reduce the risk of regain:

Gradual tapering rather than abrupt cessation. Stopping Mounjaro suddenly removes its appetite-suppressing and metabolic effects overnight. A structured taper, reducing the dose incrementally over weeks or months, allows the body to adjust more gradually. If you are considering stopping treatment, our guide on how to safely come off Mounjaro after weight loss outlines a doctor-supervised tapering approach in detail.

Establishing exercise habits during treatment. Building a consistent exercise routine while on Mounjaro creates a foundation that persists after discontinuation. Resistance training is particularly valuable because it preserves lean muscle mass, supporting a higher resting metabolic rate. For guidance on structuring your training, see our article on exercise on Mounjaro.

Dietary restructuring during the treatment window. The period on Mounjaro offers a unique opportunity to reshape eating habits while appetite is suppressed. Patients who adopt a higher-protein, nutrient-dense diet during treatment tend to fare better after stopping, as protein supports satiety and muscle preservation independently of medication.

Ongoing clinical monitoring. Regular follow-up with a weight management clinician allows early detection of regain and timely intervention, whether that means restarting medication at a lower dose, adjusting dietary targets, or intensifying exercise.

One limitation of relying solely on scales is that body weight tells you nothing about what you are regaining. If weight returns as fat rather than muscle, the metabolic consequences are worse than the number suggests. Conversely, if a patient gains some weight but maintains lean mass through resistance training, the health impact is substantially less concerning.

For this reason, I recommend that patients transitioning off Mounjaro consider periodic body composition assessments. DEXA London, CutKilo’s sister service, offers clinical-grade DEXA scans that precisely quantify fat mass, lean mass, and visceral fat. These scans provide objective data to guide decisions about whether to adjust your maintenance strategy, restart medication, or stay the course.

Monitoring visceral fat is especially important. The SURMOUNT-4 data showed that waist circumference, a proxy for visceral adiposity, increased significantly with weight regain. Visceral fat surrounds internal organs and its accumulation is strongly linked to insulin resistance and cardiovascular disease. Catching an upward trend early gives you the best chance of intervening before cardiometabolic parameters deteriorate.

How quickly does weight come back after stopping Mounjaro? Significant regain typically begins around eight weeks after discontinuation. The SURMOUNT-4 data showed an average regain of 14 percentage points over 12 months, with a Cambridge meta-analysis estimating a rate of approximately 0.8 kg per month.

Is weight regain after stopping Mounjaro inevitable? Not entirely. While 82.5% of SURMOUNT-4 participants regained at least 25% of their lost weight, 17.5% managed to keep their regain below that threshold. Success is more likely when patients taper gradually, maintain exercise habits, follow a high-protein diet, and receive ongoing clinical support.

Do the health benefits of Mounjaro disappear when you stop taking it? Largely, yes. The SURMOUNT-4 post-hoc analysis showed that improvements in blood pressure, HbA1c, cholesterol, and fasting insulin all reversed in proportion to weight regain. Some parameters worsened even in those who maintained most of their weight loss, suggesting tirzepatide has direct pharmacological effects beyond weight reduction.

Should Mounjaro be taken for life? Current expert consensus, including the 2025 ACC Expert Consensus Statement, treats obesity as a chronic disease that may require long-term pharmacological management. This does not necessarily mean the same dose forever. Some patients do well on a reduced maintenance dose, while others transition off successfully with robust lifestyle support. The decision should be individualised with your prescribing clinician.

Can you restart Mounjaro after stopping? Yes. Real-world data shows that roughly 42% of patients who discontinue GLP-1 receptor agonists restart within a year. There is no contraindication to restarting, though you will typically need to re-titrate from a lower dose. Discussing a restart plan with your doctor early helps minimise the period of uncontrolled regain.

The SURMOUNT-4 post-hoc analysis confirms what many clinicians have long suspected: weight regain after stopping Mounjaro is the norm rather than the exception. With 82.5% of participants regaining at least a quarter of their lost weight within a year, and cardiometabolic improvements reversing in tandem, the case for treating obesity as a chronic condition requiring sustained management is stronger than ever.

However, these findings should not discourage anyone from starting treatment. The metabolic benefits of Mounjaro are substantial and well-documented. Instead, the data underscores the importance of planning for the long term from the outset. Whether that means continued medication, a comprehensive lifestyle foundation built during treatment, or a structured doctor-supervised taper, preparation is what separates those who maintain their progress from those who do not.

At CutKilo, we support our patients through every phase of their weight-loss journey, including the transition off medication. If you are considering starting Mounjaro or thinking about stopping, I encourage you to speak with a clinician who understands the nuances of this decision.

Dr Emil Gadimali